NZ303914A - Method for treating amyloidosis - Google Patents

Method for treating amyloidosis

Info

Publication number
NZ303914A
NZ303914A NZ303914A NZ30391496A NZ303914A NZ 303914 A NZ303914 A NZ 303914A NZ 303914 A NZ303914 A NZ 303914A NZ 30391496 A NZ30391496 A NZ 30391496A NZ 303914 A NZ303914 A NZ 303914A
Authority
NZ
New Zealand
Prior art keywords
acid
carrier molecule
groups
group
compounds
Prior art date
Application number
NZ303914A
Other languages
English (en)
Inventor
Robert Kisilevsky
Walter Szarek
Donald Weaver
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/403,230 external-priority patent/US5643562A/en
Priority claimed from US08/463,548 external-priority patent/US5972328A/en
Application filed by Univ Kingston filed Critical Univ Kingston
Publication of NZ303914A publication Critical patent/NZ303914A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ303914A 1995-03-15 1996-03-15 Method for treating amyloidosis NZ303914A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/403,230 US5643562A (en) 1993-03-29 1995-03-15 Method for treating amyloidosis
US08/463,548 US5972328A (en) 1993-03-29 1995-06-05 Method for treating amyloidosis
US08/542,997 US5840294A (en) 1993-03-29 1995-10-13 Method for treating amyloidosis
PCT/CA1996/000179 WO1996028187A1 (en) 1995-03-15 1996-03-15 Method for treating amyloidosis

Publications (1)

Publication Number Publication Date
NZ303914A true NZ303914A (en) 2000-12-22

Family

ID=27410534

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ303914A NZ303914A (en) 1995-03-15 1996-03-15 Method for treating amyloidosis

Country Status (13)

Country Link
US (1) US5840294A (OSRAM)
EP (2) EP0814842B1 (OSRAM)
JP (3) JP3623236B2 (OSRAM)
AT (1) ATE306282T1 (OSRAM)
AU (1) AU716218B2 (OSRAM)
BR (1) BR9607197A (OSRAM)
CA (1) CA2213759C (OSRAM)
DE (1) DE69635271T2 (OSRAM)
DK (1) DK0814842T3 (OSRAM)
ES (1) ES2250985T3 (OSRAM)
NZ (1) NZ303914A (OSRAM)
SI (1) SI0814842T1 (OSRAM)
WO (1) WO1996028187A1 (OSRAM)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
CA2301725C (en) * 1997-08-28 2008-11-18 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
ES2392391T3 (es) * 1998-02-11 2012-12-10 Bhi Limited Partnership Método para modular la activación de macrófagos
AU2006228064C1 (en) * 1998-02-11 2009-01-29 Bhi Limited Partnership Method for modulating macrophage activation
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
MXPA00011213A (es) * 1998-05-15 2003-04-22 Neurochem Inc Uso de inhibidores de amiloides para la modulacion de la muerte de las celulas neuronales.
AU2006203051C1 (en) * 1998-05-15 2009-01-22 Bhi Limited Partnership Use of amyloid inhibitors for modulating neuronal cell death
EP1609467A1 (en) * 1998-07-28 2005-12-28 Neurochem (International) Limited Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
JP4726304B2 (ja) * 1999-04-28 2011-07-20 ベルス ヘルス （インターナショナル） リミティッド アミロイドーシスを治療するための組成物および方法
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
AU2005203635B2 (en) * 1999-05-24 2008-08-07 Bellus Health (International) Limited Methods and compounds for inhibiting amyloid deposits
EP1237547A2 (en) * 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US6310048B1 (en) 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
BR0016652A (pt) * 1999-12-23 2002-11-19 Neurochem Inc Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
JP2005231998A (ja) * 2000-02-01 2005-09-02 Zeria Pharmaceut Co Ltd 透析アミロイド線維重合核の製造方法及び透析アミロイド−シス治療剤のスクリーニング方法並びに透析アミロイドーシス治療剤
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
WO2003017994A1 (en) * 2001-08-31 2003-03-06 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
JP4662719B2 (ja) 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
EP2527315B1 (en) 2002-05-31 2014-03-19 Proteotech Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
US20040057949A1 (en) * 2002-09-23 2004-03-25 Depaolis Potito U. Hemodialysis method for improving immune system function
EA012325B1 (ru) * 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
NZ544686A (en) * 2003-06-23 2010-03-26 Bellus Health International Ltd Improved pharmaceutical drug candidates and methods for preparation thereof
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
SI1646659T1 (sl) * 2003-06-23 2014-07-31 Kiacta Sarl Postopek za pripravo spojin 1,3-propan disulfonske kisline
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
WO2005000288A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
CA2529257C (en) * 2003-06-23 2013-04-23 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
JP4753022B2 (ja) * 2004-02-17 2011-08-17 独立行政法人産業技術総合研究所 プリオン増殖抑制剤
WO2005095633A1 (en) * 2004-04-02 2005-10-13 Queen's University At Kingston A cell culture system for modelling serum amyloid a amyloidogenesis and identifying amyloid modulating compounds
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
US20080306166A1 (en) * 2004-11-17 2008-12-11 Mclaurin Joanne Compositions and Methods For Treatment of Disorders of Protein Aggregation
JP5145537B2 (ja) 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
JP2009510050A (ja) * 2005-09-30 2009-03-12 ベルス ヘルス （インターナショナル） リミティッド カルボキシアルキルスルホン酸を含む薬学的組成物および方法
JP2009511568A (ja) * 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
DE602006016990D1 (de) * 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
EA200801967A1 (ru) * 2006-03-09 2009-04-28 Ворэта Фармэсьютиклз Инк. Дозированная лекарственная форма на основе циклогексанового полиола (варианты), способ ее получения, способ лечения болезни альцгеймера с ее помощью и циклогексановый полиол в качестве средства при изготовлении лекарственного средства
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP5607930B2 (ja) * 2006-10-12 2014-10-15 ビーエイチアイ リミテッド パートナーシップ ３−アミノ−１−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
WO2008061373A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008078176A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
AR060412A1 (es) * 2007-04-10 2008-06-18 Creactivar S A Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso
AR060411A1 (es) * 2007-04-10 2008-06-18 Creactivar S A Una composicion farmaceutica utilizable en el tratamiento o prevencion de una enfermedad pulmonar y uso de la n-sulfoetilnicotinamida en el tratamiento o prevencion de dicha enfermedad
WO2008124931A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
EP2656839A1 (en) * 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
WO2008124929A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES
CA2683548A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2445590T3 (es) 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
EP2349233A4 (en) * 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION
AU2010282170B2 (en) * 2009-08-10 2015-04-23 Bhi Limited Partnership Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CN103977405A (zh) * 2009-09-17 2014-08-13 北德克萨斯医学联合会 N-2-羟基-乙基-哌嗪-n’-2-乙磺酸（hepes）在疼痛控制和脱髓鞘损伤逆转中的作用
EP2470510B1 (en) 2009-09-30 2014-05-14 TransTech Pharma, LLC Substituted imidazole derivatives for treatment of alzheimers disease.
KR101173677B1 (ko) * 2009-12-11 2012-08-13 한국과학기술연구원 Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2018156845A1 (en) * 2017-02-24 2018-08-30 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN109394746A (zh) * 2017-08-15 2019-03-01 江西青峰药业有限公司 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
RS65022B1 (sr) * 2018-08-01 2024-01-31 Alzheon Inc Derivati sulfopropanske kiseline za lečenje neurodegenerativnih poremećaja
FI3829563T3 (fi) 2018-08-01 2025-02-17 Alzheon Inc 3-sulfopropaanihappo neurodegeneratiivisten sairauksien hoitamiseksi
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448779A (en) * 1981-07-16 1984-05-15 Sanofi Use of MS salt in geriatric medicine
JPH0667472B2 (ja) * 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
JP2761048B2 (ja) * 1989-08-25 1998-06-04 三共株式会社 神経成長因子産生促進剤
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
JP2980749B2 (ja) * 1990-11-30 1999-11-22 協和醗酵工業株式会社 フラン誘導体
WO1992014456A1 (en) * 1991-02-22 1992-09-03 Shapiro Howard K Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JP3295423B2 (ja) * 1992-05-29 2002-06-24 ザ ユニバーシティ オブ ブリティッシュ コロンビア 痴呆の処置のためのダプソーン及びプロミン
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ATE311864T1 (de) * 1993-03-29 2005-12-15 Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis
DE4427813C2 (de) * 1994-08-05 1996-07-11 Boewe Systec Ag Papierhandhabungssystem

Also Published As

Publication number Publication date
JPH11501635A (ja) 1999-02-09
WO1996028187A1 (en) 1996-09-19
US5840294A (en) 1998-11-24
BR9607197A (pt) 1997-11-11
SI0814842T1 (sl) 2006-04-30
JP3623236B2 (ja) 2005-02-23
DE69635271D1 (de) 2006-02-23
CA2213759A1 (en) 1996-09-19
DE69635271T2 (de) 2006-07-27
EP0814842B1 (en) 2005-10-12
EP1614432A3 (en) 2009-04-01
JP2008101020A (ja) 2008-05-01
AU5097696A (en) 1996-10-02
ES2250985T3 (es) 2006-04-16
ATE306282T1 (de) 2005-10-15
EP1614432A2 (en) 2006-01-11
JP2004115539A (ja) 2004-04-15
EP0814842A1 (en) 1998-01-07
AU716218B2 (en) 2000-02-24
MX9706986A (es) 1998-06-30
CA2213759C (en) 2011-06-07
DK0814842T3 (da) 2005-11-28

Similar Documents

Publication Publication Date Title
NZ303914A (en) Method for treating amyloidosis
EP1614416A3 (en) Method for treating amyloidosis
NO931526L (no) Cykliske iminoderivater, fremgangsmaate for deres fremstilling, og legemiddelpreparater inneholdende dem
GR3020396T3 (en) Pharmaceutical formulation and process
AP9701041A0 (en) Pyridylpyrrole compounds.
NO174806C (OSRAM)
CA2186502A1 (en) Artificial Tanning Compositions Having Improved Color Development
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
KR960703411A (ko) 1-데아미노-8-d-아르기닌 바소프레신의 제조 방법
KR960700269A (ko) 신규한 펩티드(New Peptides)
US5231082A (en) Cyclic peptide with anti-metastasis activity
ATE118017T1 (de) Aglykone von a/16686-antibiotika.
MY110004A (en) Biologically active ureido derivatives useful as antimetastatic agents.
DE69603771D1 (de) Substituierte Indenoylguanidines mit antiarrhythmischer und cardioprotektiver Wirkung
SE8605573D0 (sv) Novel compounds
BR9912051A (pt) Uso de composto, e, processo para tratamento e prevenção de discinesia.
KR890007752A (ko) 빈크리스틴-함유 생성물
DE3750117D1 (de) Verfahren zur Herstellung von Indolinon-2-Derivaten.
AU767971B2 (en) Inhibition of toxic materials or substances using dendrimers
NO922094L (no) Heksapeptider med sulfatestergrupper
HARADA et al. Retention in the body of various o-acylthiamine disulfides and several properties of o-butyryl-thiamine disulfide
MX9707673A (es) Derivados de ureido biologicamente activos, eficaces en el tratamiento de la esclerosis multiple.
TH8967A (th) ไพโรลที่ถูกแทนที่

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BELLUS HEALTH INC., CA

Free format text: OLD OWNER(S): BELLUS HEALTH (INTERNATIONAL) LIMITED

ASS Change of ownership

Owner name: BHI LIMITED, CA

Effective date: 20130130

EXPY Patent expired